| __timestamp | Eli Lilly and Company | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 4042025 |
| Thursday, January 1, 2015 | 6533000000 | 5279557 |
| Friday, January 1, 2016 | 6452000000 | 8073913 |
| Sunday, January 1, 2017 | 6588100000 | 44864073 |
| Monday, January 1, 2018 | 5975100000 | 53488904 |
| Tuesday, January 1, 2019 | 6213800000 | 65896361 |
| Wednesday, January 1, 2020 | 6121200000 | 69968267 |
| Friday, January 1, 2021 | 6431600000 | 92047281 |
| Saturday, January 1, 2022 | 6440400000 | 131819000 |
| Sunday, January 1, 2023 | 6941200000 | 87501000 |
| Monday, January 1, 2024 | 8593800000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants is crucial. Eli Lilly and Company, a stalwart in the sector, has consistently demonstrated robust financial management. From 2014 to 2023, their Selling, General, and Administrative (SG&A) expenses have shown a steady increase, peaking at approximately $6.94 billion in 2023. This represents a growth of about 5% from their 2014 figures.
In contrast, Pharming Group N.V., a smaller player, has seen a dramatic rise in SG&A expenses, skyrocketing from a modest $4 million in 2014 to over $131 million in 2022. This exponential increase highlights their aggressive expansion strategy, marking a staggering 3,150% growth over the period.
These trends underscore the diverse strategies employed by pharmaceutical companies in managing operational costs, reflecting their unique market positions and growth trajectories.
Eli Lilly and Company or Insmed Incorporated: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Viatris Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Sarepta Therapeutics, Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ACADIA Pharmaceuticals Inc.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Pharming Group N.V.
Pharming Group N.V. and Madrigal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Pharming Group N.V. and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Pharming Group N.V. vs ADMA Biologics, Inc.
Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?